Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules. More Details
+ 1 more risk
Flawless balance sheet and undervalued.
Share Price & News
How has Co-Diagnostics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: C97 is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: C97's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
7 Day Return
DE Medical Equipment
1 Year Return
DE Medical Equipment
Return vs Industry: C97 underperformed the German Medical Equipment industry which returned 41.5% over the past year.
Return vs Market: C97 underperformed the German Market which returned 42.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Co-Diagnostics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Co-Diagnostics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: C97 (€7.48) is trading below our estimate of fair value (€161.23)
Significantly Below Fair Value: C97 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: C97 is good value based on its PE Ratio (5.5x) compared to the DE Medical Equipment industry average (46.3x).
PE vs Market: C97 is good value based on its PE Ratio (5.5x) compared to the German market (28.2x).
Price to Earnings Growth Ratio
PEG Ratio: C97's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: C97 is good value based on its PB Ratio (3.8x) compared to the DE Medical Equipment industry average (7.9x).
How is Co-Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: C97's earnings are forecast to decline over the next 3 years (-43.6% per year).
Earnings vs Market: C97's earnings are forecast to decline over the next 3 years (-43.6% per year).
High Growth Earnings: C97's earnings are forecast to decline over the next 3 years.
Revenue vs Market: C97's revenue is expected to decline over the next 3 years (-1.3% per year).
High Growth Revenue: C97's revenue is forecast to decline over the next 3 years (-1.3% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if C97's Return on Equity is forecast to be high in 3 years time
How has Co-Diagnostics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: C97 has a high level of non-cash earnings.
Growing Profit Margin: C97 became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: C97 has become profitable over the past 5 years, growing earnings by 53% per year.
Accelerating Growth: C97 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: C97 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (44.3%).
Return on Equity
High ROE: C97's Return on Equity (63.7%) is considered outstanding.
How is Co-Diagnostics's financial position?
Financial Position Analysis
Short Term Liabilities: C97's short term assets ($68.4M) exceed its short term liabilities ($4.5M).
Long Term Liabilities: C97's short term assets ($68.4M) exceed its long term liabilities ($30.0K).
Debt to Equity History and Analysis
Debt Level: C97 is debt free.
Reducing Debt: C97 currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Debt Coverage: C97 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: C97 has no debt, therefore coverage of interest payments is not a concern.
What is Co-Diagnostics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate C97's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate C97's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if C97's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if C97's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of C97's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Dwight Egan (67 yo)
Mr. Dwight H. Egan serves as the Chairman, Chief Executive Officer and President at Co-Diagnostics, Inc. and has been its Director since April 2013. Mr. Egan has been engaged in private investment business...
CEO Compensation Analysis
Compensation vs Market: Dwight's total compensation ($USD1.46M) is above average for companies of similar size in the German market ($USD564.45K).
Compensation vs Earnings: Dwight's compensation has been consistent with company performance over the past year.
Experienced Board: C97's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: C97 insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.5%.
Co-Diagnostics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Co-Diagnostics, Inc.
- Ticker: C97
- Exchange: MUN
- Founded: 2013
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$273.471m
- Listing Market Cap: US$228.403m
- Shares outstanding: 28.67m
- Website: https://www.codiagnostics.com
Number of Employees
- Co-Diagnostics, Inc.
- 2401 South Foothill Drive
- Suite D
- Salt Lake City
- United States
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules. It...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/14 20:01|
|End of Day Share Price||2021/04/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.